Table of Contents
Nufarm’s Recovery: A Strong First Half Results in Stock Surge
After a tumultuous year where Nufarm shareholders witnessed a dramatic 30% loss in a single day, the company’s stock has started to recover. A notable 13.6% increase on Wednesday has brought the share price back to its previous levels, largely due to a robust first-half performance that analysts are describing as a pivotal turning point for earnings.
This recent surge has pushed Nufarm’s stock to its highest position since 21 May 2025, a date marked by significant setbacks including abandoned revenue targets for Omega-3 products, a $28 million inventory writedown, and an alarming spike in debt leverage to 4.5 times.
Source: TradingView
Key Insights from 1H26
Nufarm’s first-half results align well with expectations, displaying improved margins, reduced capital expenditure, and a significant drop in net leverage. Here are the standout numbers:
- Revenue: Down 5% year-on-year to $1.7 billion.
- Underlying Gross Profit Margin: Increased by 3.7 percentage points to 33.0%.
- Underlying EBITDA: Up 18% to $243 million, at the peak of guidance estimates ($239-244 million).
- Underlying Net Profit After Tax (NPAT): Rose by 35% to $52 million.
- Net Debt: Reduced by $135 million to $1.23 billion.
- Leverage Ratio: Decreased by 20% to 3.6 times, with a target of 2.0 times by the end of FY26.
Additional highlights include:
- Affirmation of FY26 guidance predicting "strong growth in underlying EBITDA."
- Progress on a $50 million cost reduction programme, with an additional targeted savings of $50 million by the end of FY27, fully realised by FY28.
- Continued growth in the Crop Protection division, building on the previous half-year’s performance through ongoing margin improvements and cost efficiency.
- An upgrade in Seed Technologies FY26 EBITDA guidance to $40 million, up from $30 million.
The Seed Technologies update is significant, particularly concerning the Omega-3 canola program, which caused past stock declines. Losses in this area have decreased considerably, aided by relocating production to South America and a hike in fish oil prices. Additionally, management is eyeing potential deregulation for Omega-3 products in Europe and China by 2028.
Analyst Reactions
The first-half results have inspired a series of upgrades from analysts, with the consensus being that Nufarm is at an earnings inflection point. Recent adjustments include:
- UBS: Upgraded to Buy from Neutral, target raised from $2.80 to $3.50, citing sustainable margins and growth in emerging platforms, bolstered by cost management strategies.
- RBC Capital Markets: Upgraded to Outperform from Sector Perform, with a target increase from $3.40 to $3.60, focusing on improved capital efficiency and a commitment to maximising returns over sheer volume.
- Bell Potter: Maintained a Buy rating with a target of $3.60, recognising strong revenue growth from hybrid seeds and emerging platforms alongside successful cost management.
Future Prospects
Nufarm is navigating a significant turnaround, currently trading at a notable discount compared to global competitors—an EV/EBITDA of 5.7 times versus 9.2 times for its peers, according to Macquarie’s April analysis. While this gap presents an investment opportunity, the company must consistently deliver positive results to close this valuation discount.
In summary, Nufarm’s strategic initiatives, operational improvements, and the positive reception of its recent financial results signal a hopeful outlook as it charts a course towards recovery and growth.
